Introduction {#Sec1}
============

Neural tube defects (NTDs) are the second most common group of serious birth defects. NTDs result from failure of the neural tube to close properly, approximately 28 days postconception. Typically, this occurs before the woman knows that she is pregnant \[[@CR7], [@CR38]\]. Despite the identified association between the achievement of adequate folate level at time of conception and a risk reduction of NTDs, NTDs have a complex and imperfectly understood aetiology in which both genetic and environmental factors appear to be involved \[[@CR7]\].

Two of the most common NTDs are spina bifida and anencephaly. Spina bifida results from failure of fusion of the posterior (caudal) neural tube, whereas anencephaly results from failure of fusion of the anterior (cranial) neural tube. Anencephaly is fatal; many children with anencephaly are stillborn or die shortly after birth. Fifty percent have a life expectancy of between a few minutes and 1 day, and 25% only live up to 10 days \[[@CR29]\]. Children with spina bifida have a high probability of lifelong physical and mental handicap, and only a minority of these children are able to function independently as adults \[[@CR41]\]. Due to advances in medical technology, the life expectancy of patients with spina bifida is rising annually, with 85% to 90% of children born with the disease surviving into adulthood \[[@CR46]\].

Patients with NTDs regularly have problems related to hydrocephalus, neurogenic bladder, kidney involvement, the orthopaedic complications, and the psychosocial consequences. These complications can cause severe disability, which add significant burden to patients with NTDs and their families.

Each year, 300,000 to 400,000 infants worldwide are born with spina bifida and anencephaly \[[@CR16]\]. Approximately 4,500 pregnancies every year in Europe result in a baby or foetus affected by an NTD, and in the USA, 2,500 live births are affected by NTDs each year \[[@CR51]\]. In China, 100,000 infants are born annually with NTDs \[[@CR7]\].

Treatment for spina bifida includes surgery, medication, and physiotherapy. Surgery to close the newborn's spinal opening is generally performed within 24 h after birth to minimize the risk of infection and to preserve existing function in the spinal cord. However, regular monitoring, ongoing therapy, and medical and/or surgical treatments are often necessary to prevent and manage complications throughout the individual's life. Although many advances have been made in the treatment of spina bifida, resulting in increased life expectancy and improved quality of life for individuals with the disease, no treatment exists that will completely eliminate the serious disability or premature mortality associated with it. For these reasons, reducing the risk of NTDs is an important goal.

Most cases of anencephaly and spina bifida can be detected through prenatal screening methods such as second trimester maternal serum alpha-fetoprotein screening and foetal ultrasound scanning \[[@CR33]\]. However, parents face great distress at the diagnosis of an NTD, confronting either the grief of a termination or stillbirth or the extensive emotional and financial challenges of caring for a child with NTD \[[@CR32]\].

Folic acid has been shown to reduce effectively the risk of NTDs in 1990s \[[@CR5]\], and this is supported by the evidence from recent systematic reviews on folic acid for the prevention of NTDs in both high- and low-income countries \[[@CR6], [@CR52]\]. Although not all cases of NTDs can be prevented by increasing the intake of folic acid due to a 'floor effect' \[[@CR26]\], studies have suggested that 50% to 70% of cases could be prevented by the appropriate consumption of folic acid before conception and during early pregnancy \[[@CR7]\]. In 1992, the US Public Health Service recommended that all women capable of becoming pregnant consume 0.4 mg (or 400 μg) of folic acid daily to reduce their risk for having a pregnancy affected by NTDs \[[@CR10]\]. In 1998, the US Food and Drug Administration mandated that folic acid be added to cereal grain products, and a number of media campaigns, health advisory groups \[[@CR11]\], and worldwide public health campaigns have been launched to increase the awareness, knowledge, and consumption of folic acid. As a result, the incidence and prevalence of NTDs have declined and stabilized in many countries \[[@CR9], [@CR12], [@CR13], [@CR15], [@CR20], [@CR21], [@CR27], [@CR35], [@CR36], [@CR42], [@CR54]\]. While food fortification with folic acid is well established in the USA, Canada, and Chile, in Europe, the discussion, including what is the optimal approach, is still ongoing. Moreover, racial/ethnic disparities and socioeconomic and educational issues in the consumption of folic acid persist, and differences of supplement use by age exist \[[@CR37]\]. Therefore, the full potential of folic acid to reduce the risk of NTDs has not yet been realized, and preventable NTDs continue to occur.

Patients with NTDs are at risk of psychosocial problems and have acute, lifelong disabilities, which require a lifetime of medical care \[[@CR19], [@CR55]\]. Cost of illness studies attempts to quantify the economic burden of a disease and estimate all the costs associated with a particular disease. These studies provide information on the economic burden to society or to a specific stakeholder such as the healthcare payer or the patient. Economic evaluation studies evaluate whether the effectiveness or benefit of intervention is worth the cost of implementing the intervention. These studies provide information for decision makers to determine the best way of allocating scarce healthcare resources to ensure a given population receives optimal healthcare.

This paper summarizes the economic evidence from a systematic review that was conducted to understand the humanistic and economic burden of NTDs to healthcare systems, patients, caregivers, and society. While humanistic patient-reported outcome and caregiver burden are focuses of other papers, the objective of this paper is to gain greater insight into the economic burden of NTDs both on healthcare systems and on wider society and to understand the cost-effectiveness of folic acid for the prevention of NTDs.

Methods {#Sec2}
=======

A literature review was conducted using a standard systematic approach \[[@CR14]\]. To identify relevant studies associated with costs of NTDs and economic evaluations of folic acid for the prevention of NTDs, electronic databases (PUBMED, PsycINFO, and Embase) were searched for material dating from January 1976 to October 2010, using the following search terms: ○ Neural tube defects OR NTDs OR spina bifida OR anencephaly OR meningocele AND○ Cost OR economic OR financial burden/impact of illness/disease OR resource use OR hospitalization OR○ Economic evaluation OR cost analysis OR cost effectiveness OR CEA OR cost minimisation OR CMA OR cost consequence OR CCA OR cost utility OR CUA OR cost benefit OR CBA OR cost savings OR patient preferences AND○ Folic acid OR folate OR vitamin supplements OR food fortifi\* OR enriched grain

The Health Economic Evaluation Database and the Centre for Review and Dissemination databases (NHS Economic Evaluation Database and Health Technology Assessment (HTA)) were also searched in addition to the websites of the major HTA bodies (such as the International Network of Agencies for Health Technology Assessment, National Institute for Health and Clinical Excellence, and Scottish Medicines Consortium in the UK, Institute for Quality and Efficiency in Health Care in Germany, Pharmaceutical Benefits Advisory Committee in Australia, and Canadian Agency for Drugs and Technologies in Health in Canada). The search was limited to English language articles.

Studies identified for inclusion in the review were cost of illness studies reporting resource use and costs associated with NTDs and complications, and economic evaluations estimating both the costs and effects of prevention of NTDs with folic acid. Data were extracted by one researcher using a structured data extraction form and checked by a second researcher. The quality of studies included in the review was assessed using published checklists \[[@CR17], [@CR39]\].

All costs have been inflated and converted from local currencies to 2011 Euro (€) using the Consumer Price Index (CPI) inflation calculators (<http://www.bls.gov/data/inflation_calculator.htm>, <http://www.rba.gov.au/calculator/annualDecimal.html> and <http://www.rbnz.govt.nz/statistics/0135595.html>) and currency converter at the exchange rate on 26 April 2011 (i.e. \$1 = €0.6856, \$AU1 = €0.7363 and \$NZ1 = €0.5427) (<http://www.foreign-currency-uk.com/currency_converter.asp>). Actual costs reported in different studies are presented in the brackets. Moreover, the cost per patient was calculated where possible in order to compare the different studies and their varying sample sizes. Where costs have been converted into Euro from other currencies, these costs should only be used as a guide because official exchange rates do not adequately reflect the comparative purchasing power of the local currencies in their own markets \[[@CR17]\].

Results {#Sec3}
=======

Literature search results {#Sec4}
-------------------------

Fourteen cost of illness studies (12 from the USA, 1 each from Canada and Spain) and 10 economic evaluations on prevention with folic acid (4 from the USA, 2 from both Chile and the Netherlands, 1 each from Australia/New Zealand and South Africa) were identified for this review (Fig. [1](#Fig1){ref-type="fig"}). Fig. 1Selection of the studies reviewed

The quality of the cost of illness studies was generally poor. This was largely due to the limited range of costs that were included in these studies and lack of any sensitivity analyses to assess the robustness of results. However, despite these limitations, the overarching results from these studies are consistent.

Overall, the quality of the economic evaluations was higher. Most of them were carried out using standard and recommended methodology. However, there were wide differences in the way that 'benefits' were measured across the studies such that it was not appropriate to make comparisons between studies.

Economic burden of NTDs {#Sec5}
-----------------------

Table [1](#Tab1){ref-type="table"} describes the range of costs that were included in each of the cost of illness studies. The majority of studies included the medical costs of NTDs, and seven focused solely on these costs. These are costs that are borne by healthcare payers such as health insurance programmes, and include factors such as drugs and hospitalizations both for managing NTDs directly and for managing comorbidities. The studies by Waitzman et al. \[[@CR49], [@CR50]\] are more inclusive and take into account costs associated with development services and special education for individuals living with NTDs. These types of costs are often described as direct nonmedical costs. Broader costs such as lost work time, caregiver costs, and costs due to premature loss of life were considered in the studies by Waitzman et al. \[[@CR49], [@CR50]\], Lipscomb et al. \[[@CR34]\] and Tilford et al. \[[@CR47], [@CR48]\]. These are typically referred to as indirect costs. The study by Young \[[@CR53]\] only reported resource use of adult patients with spina bifida in Canada without cost information. Table 1Summary of NTD cost of illness studies reviewed (annual cost per patient in 2011€)ReferencesCountryDirect medical costsDirect nonmedical costsCaregiver time costsIndirect costsLipscomb 1986 \[[@CR34]\]USA----Average reductions of 14 h per week in paid work time for mothers and 5 h per week for fathers--Harris et al. 1990 \[[@CR24]\]USASkin breakdown in myeloeningocele: €2,466 (1,763 in 1986\$)------Bea et al. 1994 \[[@CR3]\]SpainMyeloeningocele: €3,541 (2,734 in 1988\$)------Waitzman et al. 1996 \[[@CR50]\]USASB: age 0--1: €33,213 (34,013 in 1996\$); age 2--4: €14,573 (14,924 in 1996\$); age 5--17: €12,897 (13,208 in 1996\$); age 18+: €4,095(4,194 in 1996\$)SB: total per capita lifetime cost for development and special education--Average lifetime cost per case of SBKinsman et al. 1996 \[[@CR31]\]USAAll comorbidity in SB: €4,873 (4,462 in 1992\$)------Ireys et al. 1997 \[[@CR28]\]USASB: €11,728 (11,061 in 1993\$)------Tilford et al. 2001 \[[@CR48]\]USA----Caregiver time costs for a case of SB: €112,901 to €135,743 (\$164,675 to \$197,991, price year not clear)--Waitzman et al. 2004 \[[@CR49]\]USAAverage lifetime cost per case of SBAverage lifetime cost per case of SB for development and special education--Average lifetime cost per case of SBOuyang et al. 2007 \[[@CR40]\]USASB: €13,248 (15,911 in 2003\$)------Robbins et al. 2007 \[[@CR43]\]USANTD: €42,943 (51,574 in 2003\$); SB: €54,270 (65,177 in 2003\$); Anencephaly: €3,131 (3,760 in 2003\$); Encephalocele: €37,509 (45,047 in 2003\$)------Armour et al. 2009 \[[@CR1]\]USAPeople with SB treated for urinary tract infection---an ambulatory care sensitive condition: average Medical Care expenditure for hospitalization €8,274 and for ambulatory care €370 (9,300 and 416 in 2000\$, respectively); patient out-of-pocket for hospitalization €623 and €75 for ambulatory care (700 and 84 in 2000\$, respectively)------Tilford et al. 2009 \[[@CR47]\]USA----Caregivers of children with SB worked an annual average of 7.5 to 11.3 h less per week depending on the disability severity. This translated into lifetime costs of €113,910 (133,755 in 2002\$) using a 3% discount rate and an age- and sex-adjusted earnings profile--Bamer et al. 2010 \[[@CR2]\]USA--Average annual Medicaid cost of AT was €347 (\$494, price year not clear) per enrolee with SB and AT accounted for 3.3% of all Medicaid costs for them. AT-related costs were highest for those aged 0--15 years and lowest for those aged 16--25 years----Young 2005 \[[@CR53]\]CanadaOnly reported resource use: over 95% of adult patients with SB were seen by a physician each year; Outpatient physician visits: 8.99 office appoints and 0.47 emergency department visits per person per year; Inpatient admission: one admission for each patient every 5.7 years.*AT* assistive technology, *NTD* neural tube defect, *SB* spina bifida

Annual direct medical cost per patient was estimated to be €42,943 (\$51,574 in 2003\$) for NTD \[[@CR43]\] and between €11,728 (\$11,061 in 1993\$) to €54,270 (\$65,177 in 2003\$) for spina bifida \[[@CR28], [@CR40], [@CR43]\] in the USA. In Spain, the Social Security system spent direct medical costs of €3,825,037 (\$2,953,138 in 1988\$) per year for the care of patients with spina bifida \[[@CR3]\], representing approximately €3,541 (\$2,734 in 1988\$) per person per year.

A significant proportion of the cost burden occurs during childhood. For example, in the USA, total hospital charges for new born infants with NTDs amounted to €62 million for spina bifida, €1 million for anencephaly and €9 million for encephalocele (\$74 million, \$1 million and \$11 million in 2003\$, respectively) \[[@CR43]\]. More specifically, the Medicaid in Washington State spent €2 million (\$2.1 million in 1993\$) on children with spina bifida in 1993, and average payments for children with spina bifida were 11.6 times higher than the average payment for all children in the state's Medicaid programme \[[@CR28]\].

While children and adolescents with spina bifida incur medical expenditures several times higher than children and adolescents without the disease \[[@CR28], [@CR49]\], young adults with the condition also continue to be high users of medical care \[[@CR53]\]. Adults account for 67% of persons with spina bifida and 66% of medical expenditures associated with spina bifida in USA \[[@CR40]\]. At any age, individuals with spina bifida incur higher medical expenditures than those without, and costs continue to be high throughout adulthood \[[@CR40]\] (Fig. [2](#Fig2){ref-type="fig"}). Fig. 2Annual per patient medical expenditures in 2011€: persons with vs. without spina bifida

Almost half of the hospital admissions for adults with spina bifida are due to secondary conditions (such as serious urologic infections, renal calculi, pressure ulcers, and osteomyelitis), and the financial costs of these admissions are substantial \[[@CR31]\]. The annual direct medical cost per patient for the treatment of spina bifida comorbidities in the USA ranged between €2,466 \[[@CR24]\] and €4,873 \[[@CR31]\]. In Canada, Young \[[@CR53]\] reported that hospital admission rate for adults with chronic and complex physical disabilities of childhood including spina bifida is nine times that of the general population, and adult patients with spina bifida are regular users of outpatient and inpatient services (Table [1](#Tab1){ref-type="table"}).

Individuals with spina bifida often require walking aids and wheelchairs for functional mobility. In the USA in any given year, on average, 33% of individuals with spina bifida made claims from Medicaid for some type of mobility-related assistive technology, including wheelchair-related costs, orthotics and prosthetics, ambulatory aids, and communication and hearing aids \[[@CR2]\]. Annually, these claims accounted for €297,704 (price year not reported), which represents approximately 3.3% of all reimbursement by Medicaid for all medical care for these individuals \[[@CR2]\].

Five studies, which looked beyond the direct costs incurred by the healthcare system when evaluating the burden of NTDs, suggest that indirect costs of spina bifida are substantial. Tilford et al. found \[[@CR48]\] a substantial impact of caring for a child with spina bifida on labour force participation, with participation rates 21% to 27% lower than those individuals in the control group (population from the Current Population Survey covering the state of Arkansas). Caregivers of children with spina bifida worked an annual average of 7.5 to 11.3 h less per week depending on disability severity. Differences in work hours by caregivers of children with spina bifida translated into lifetime costs of €95,186 (\$111,755 in 2002\$) using a 3% discount rate and an age- and sex-adjusted earnings profile. Lipscomb et al. estimated an average reduction of paid work time of 14 h per week for mothers and 5 h per week for fathers of children with spina bifida \[[@CR34]\]. The estimated caregiver time costs to care for a children with spina bifida until age 25 ranges from €142,477 to €171,303 (\$164,675 to \$197,991 in 2001\$) depending on the discount rates used in estimating the present value of future costs \[[@CR47]\].

Total lifetime costs for patients with spina bifida amounted to €528,425 (\$620,484 in 2002\$) \[[@CR50]\]. Just 37.1% of the total was attributable to direct medical costs (€187,859 (\$220,560)), with the costs associated with special education and development services accounting for 6.5% (€35,204 (\$41,337)) and 0.3% (€1,732 (\$2,034)), respectively. The remaining 56.1% of the total were indirect costs (€303,690 (\$356,553)), of which €117,613 (\$138,086) were due to increased morbidity and €186,085 (\$218,477) due to premature mortality \[[@CR50]\].

Economic impact of preventing NTDs with folic acid {#Sec6}
--------------------------------------------------

Although there is a limited research in this field, the available evidence indicates that the economic burden of NTDs is substantial. A reduction in the incidence and prevalence of NTDs would reduce this economic burden. Very few studies have evaluated the cost-effectiveness of prevention strategies for NTDs. In the 10 identified economic evaluation studies of folic acid for the prevention of NTDs, 8 evaluated the cost-effectiveness of folic acid fortification in foods \[[@CR4], [@CR18], [@CR23], [@CR25], [@CR30], [@CR36], [@CR44], [@CR45]\], and 2 evaluated the cost-effectiveness of periconceptional supplementation of folic acid \[[@CR22], [@CR41]\] (Table [2](#Tab2){ref-type="table"}). Nine of the studies included direct medical costs only; indirect costs and benefits were included in only one study \[[@CR44]\]. Table 2Summary of economic evaluations of folic acid for the prevention of NTDsReferencesCountryType of studiesCost estimations in 2011€Benefit estimations in 2011€DiscountingSensitivity analysisBenefit--cost ratio/CE ratio (2011€)Romano 1995 \[[@CR44]\]USACBA/CEADirect cost of folic acid fortification, cost of changing product label. Total costs range from €31--55 million (27.94--49.20 million in 1991\$)Total benefit (based on direct medical costs and rehabilitation costs averted and indirect costs averted): €137--338 million (121.5--300.9 million in 1991\$); Net benefit: €105--283 (93.6--251.7 million in 1991\$)√√4.3 to 1--6.1 to 1; €103,502--€73,126 (92,000--65,000 in 1991\$) per NTD avertedPostma 2002 \[[@CR41]\]The NetherlandsCEACost of supplementation of folic acid. Total cost: €37,721 (65,000 in 2000NLG)Benefit estimation based on avoidance of direct medical costs, costs of other health institutions and special equation costs. No indirect cost was considered√√€2,263 (3,900 in 2000NLG) per discounted life-year gainedGrosse 2005 \[[@CR23]\]USACBA/CEATotal costs folic acid fortification: €3 million (3 million in 2002\$) per yearBenefit estimation based on total number of NTDs averted, SB averted, and anencephaly averted; direct medical costs; no indirect costs were included. Total benefit: €365 million for NTDs, €282 million for spina bifida and €80 million for anencephaly (425 million, 331 million, 94 million in 2002\$ respectively). Net benefits and costs saving: €359 million for NTDs and €122 million for SB (422 million, 143 million in 2002\$ respectively)√√Not calculatedLlanos 2007 \[[@CR36]\]ChileCEA/CBATotal cost of adding folic acid to the flour and cost of monitoring system: €180,546 (208,700 in 2001I\$)Benefit estimation based on medical, rehabilitation care and developmental services; No indirect costs were included. Net cost savings of €1.99 million (2.3 million in 2001I\$)√√11.8 to 1 €1,068 (1,200 in 2001I\$) per NTD case averted; €9,516 (I\$11,000) per infant death; €77 (I\$89) per DALY avertedGrosse 2008 \[[@CR22]\]USACUATotal programme cost was approximately €132,393 (155,000 in 2003\$)A total of 35 pregnancies occurred among women who were enrolled in the programme and were fully protected by folic acid supplementation, at an average cost of roughly €3,747 (4,500 in 2003\$) per covered pregnancy√√€12,240 to €45,963 (14,700 to 55,200 in 2003\$) per QALYHertrampf 2008 \[[@CR25]\]ChileCEA/CUATotal cost of adding folic acid to the flour and cost of monitoring system: €180,546 (208,700 in 2001I\$)On the overall, fortification resulted in net cost savings of €1.56 million (1.8 million in 2001I\$)√√€1,068 (1,200 in 2001I\$) per NTD case averted; €9,516 (I\$11,000) per infant death €79 (I\$91) per DALY avertedJentink 2008 \[[@CR30]\]The NetherlandsCEA/CUAThe estimated costs for folic acid food fortification ranged from €352,580 to €775,223 (312,000 to 686,000 in 2005€)Costs avoided due to fortification, i.e. lifetime costs for infants born with NTD €274,547 to €145,523 (242,948 to 128,778 in 2005€) discounted at 4%√√Cost savings €1,168 per life year gained and cost savings of €854 per QALYSayed 2008 \[[@CR45]\]South AfricaCBAThe cost of folic acid at 2% fortification premix was €0.14 million (R1.4 million price year not clear; assuming 2008)Estimated average cost of treatment of R100,000 per case avoided during the first 3 years of life. With a 41.6% reduction 406 cases are averted per annum, resulting in a saving of €3.98 million (R40.6 million)xxCost--benefit ratio in averting NTD was 46 to 1Bentley 2008 \[[@CR4]\]USACEACosts incurred from B12 masking and fortification were €12 million (15 million in 2005\$)The benefits from fortification were 182 to 1,423 cases of NTD averted per year; the predicted annual gains of 26,000 QALY and savings of over €206 million (263 million in 2005\$) from NTD preventionx√Not calculatedDalziel 2010 \[[@CR18]\]Australia and New ZealandCEA/CUAAustralia: the discounted cost per annual ranged from €26,832(\$AU32,586 in 2006\$AU) for extended voluntary permissions to €9,306,685 (\$AU11,351,261) for mandatory fortification in; New Zealand: the same cost ranged from €4,522 (\$NZ7307 in 2006 \$NZ) to €1,835,988 (\$NZ2,966,437)Estimated 36 and 31 fewer cases of NTD per annum respectively for Australia and New Zealand√√Voluntary fortification is cost-effective, at less than €7,518 (AU\$12,500 or \$9,893 in 2006) per DALY averted; Mandatory fortification was not cost-effective for New Zealand at €83,299 (AU\$138,500 or \$109,609 in 2006) per DALY, with results uncertain for Australia, given widely varying cost estimates*CBA* cost--benefit analysis, *CEA* cost-effectiveness analysis, *DALY* disability-adjusted life year, *NTD* neural tube defect, *QALY* quality-adjusted life year, *SB* spina bifida

While it is inappropriate to compare results across the identified studies due to the differences in the measures of benefits, each individual study suggested that prevention with folic acid is cost-effective, i.e. that the benefits outweighed the cost (except for mandatory fortification for New Zealand).

In the eight economic evaluations on folic acid food fortification identified by this literature review, all concluded that fortification of food with folic acid is a cost-effective method for reducing the incidence of NTDs. As shown in Table [2](#Tab2){ref-type="table"}, the benefit--cost ratio, a measure of cost--benefit, ranged from 4.3 to 1 in USA \[[@CR44]\], 11.8 to 1 in Chile \[[@CR25], [@CR36]\] to 30 to 1 in South Africa \[[@CR45]\], suggesting that the economic benefit from the prevention of NTDs greatly exceeded the cost of folic acid fortification in these countries. The cost per NTD averted, a measure of cost-effectiveness, was estimated to range from €1,068 in Chile \[[@CR25], [@CR36]\] to €103,502 (\$65,000 to \$92,000 in 1991\$) in the USA \[[@CR44]\]. The cost savings per life year gained was estimated to be €1,168 in the Netherlands \[[@CR30]\]. The cost per disability-adjusted quality of life (DALY) averted was estimated to be close to €80 in Chile \[[@CR25], [@CR36]\] and €7,518 for voluntary fortification in Australia and New Zealand. The cost per quality-adjusted life year (QALY), a measure of cost-utility, was estimated to be €854 in the Netherlands \[[@CR30]\].

Similarly, economic evaluations suggest that periconceptional supplementation of folic acid is a good use of healthcare resources and justifies further promotion of the use of folic acid supplementation prior to pregnancy. The cost per life year gained from periconceptional supplementation of folic acid was estimated to be €2,108 (NLG 3,900 in 2000 price) in the Netherlands \[[@CR41]\]. In the USA, the cost per QALY gained from the NTD recurrence prevention programmes promoting folic acid supplementation ranged from €12,240 to €45,963 (\$14,700 to \$55,200 in 2003\$), which led the authors to conclude that the NTD recurrence prevention programme provided value for the money spent relative to other public health interventions \[[@CR22]\].

In all the countries where cost--benefit of folic acid for the prevention of NTDs was evaluated, several millions to hundreds of millions of Euros (or dollars) of net benefit or cost savings were estimated. These results strongly support the continuation of folic acid for the prevention of NTDs, especially in countries with NTD prevalence far above the observed floor for folic acid-preventable NTD \[[@CR26]\].

Discussion {#Sec7}
==========

There are some limitations to this review which deserve comment. Given the gravity of NTDs, we found surprisingly few studies that evaluated the economic burden of the disease and the economic impact of prevention with folic acid. These studies reported findings from a limited number of countries (mainly the USA) and focused on spina bifida over other NTDs. In addition, most of the studies were based on data collected more than 10 years ago and therefore may not reflect techniques currently used for prenatal diagnosis and interruption of pregnancy and management of NTDs \[[@CR8]\]. The quality of the cost of illness studies was generally poor, with few studies addressing all important aspects of cost of illness and uncertainties around the estimation of costs. Methodological differences limited comparisons between studies. Moreover, while the economic evaluations were of good quality, comparisons between studies could not be made because the measures of benefit differed.

Despite these limitations, consistent findings were reported across all studies. NTDs represent a high cost per patient to healthcare payer and society. Key cost drivers are the inpatient days at initial diagnosis in childhood and, later in life, treatment of comorbidities in survivors. The lifetime costs are significant, as patients require ongoing care throughout their lives. Patients with NTDs also require other forms of support that result in direct nonmedical costs, such as special education, developmental services and mobility-related assistive devices. Caregivers of children with spina bifida are impacted by economic factors such as a reduction of paid work time. In addition, there are significant indirect costs associated with NTDs due to the reduced productivity of the patients themselves. These results demonstrate the significant lifetime cost burden of NTDs to healthcare systems, various healthcare payers, caregivers, and society in general.

As caregiver time costs and indirect costs associated with morbidity and premature death of individuals with NTDs are significant, they should be included in economic evaluations of interventions to prevent NTDs. However, a few of the available economic evaluations of folic acid have considered caregiver time costs and indirect costs. The review found that even without considering the significant indirect costs associated with NTDs, folic acid fortification in food and preconception folic acid consumption are still cost-effective ways to reduce the incidence and prevalence of NTDs. However, the full potential of folic acid to reduce the risk of NTDs has not been realized in many countries, suggesting that more can be done to reduce greatly the incidence of the condition and its associated economic burden.

Further research is required to understand fully the economic impact of NTDs. Studies in a wider range of countries are needed, as differences in the healthcare system structure and in the management of NTDs across countries limit the generalizability of the findings from the studies reported here to other countries. In order to understand fully the burden of this disease, a broader range of costs should be measured. Outpatient care costs and broader societal costs such as nonmedical costs and the indirect costs associated with lost productivity and premature death would be of particular interest, given the limited data currently available. Moreover, in order to compare the cost-effectiveness of alternative prevention strategies, future studies should use a standard approach to the measurement of effectiveness or benefit of the prevention strategies. The use of a generic measure of benefit, for example quality-adjusted life years saved, would enable those who fund healthcare for a defined population to assess the value of alternative prevention options for NTDs and therefore fund the option that provides the maximal benefit within the funds available.

Conclusion {#Sec8}
==========

This review has highlighted the significant cost burden that NTDs pose to healthcare systems, various healthcare payers, and wider society, concluding that the benefits of preventing this condition with folic acid outweigh the costs of such initiatives. In countries where the full potential of folic acid to reduce the risk of NTDs has not been realized, further intervention with folic acid is justified.
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